Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Indinavir sulfate in preparation of medicaments for preventing or treating ischemic cardiovascular and cerebrovascular diseases

A kind of technology of indinavir sulfate, cardiovascular and cerebrovascular diseases

Inactive Publication Date: 2014-10-08
BINZHOU MEDICAL COLLEGE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Clinically, indinavir sulfate capsules are used in combination with other antiretroviral drugs to treat HIV-1 infection, but the pharmacological effects of indinavir sulfate in the prevention or treatment of ischemic cardiovascular and cerebrovascular diseases have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Indinavir sulfate in preparation of medicaments for preventing or treating ischemic cardiovascular and cerebrovascular diseases
  • Application of Indinavir sulfate in preparation of medicaments for preventing or treating ischemic cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1 Indinavir sulfate freeze-dried powder preparation

[0013] Take 30.0g of indinavir sulfate, add 2000ml of water for injection to dissolve it, add 8g of mannitol, stir to dissolve, and ultra-filter to obtain a pyrogen-free clear liquid, pour it into a 10ml vial, 2ml / bottle, press the freeze-dried powder Freeze-dried by needle process to make freeze-dried powder injections each containing 30.0 mg of indinavir sulfate.

Embodiment 2

[0014] Embodiment 2 preparation of indinavir sulfate capsules

[0015] Weigh 200.0g of indinavir sulfate and 100.0g of sodium carboxymethyl starch, mix well and pass through a 100 mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to make soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, sieve with 18-mesh sieve, add 2.0g magnesium stearate, mix well and pack into capsules, the weight of the capsules is about 300mg.

[0016] Specific test example

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new uses of medicaments and particularly relates to an application of Indinavir sulfate in the prevention or treatment of ischemic cardiovascular and cerebrovascular diseases through inhibiting the expression of HMGB1 (High Mobility Group Box 1). According to the application, the range of oral dosage is 120-6,000mg and preferably is 120-3,000mg; the range of injection dosage is 30-2,000mg and preferably is 30-1,000mg.

Description

technical field [0001] The invention relates to a new application of medicine, in particular to indinavir sulfate preventing or treating ischemic cardiovascular and cerebrovascular diseases by inhibiting the expression of HMGB1. Background technique [0002] Ischemic stroke is a major disease that seriously endangers human health. Theoretical treatment methods include: (1) Thrombolytic therapy within 3-6 hours after onset. (2) Neuroprotective treatment of secondary nerve damage caused by ischemia. (3) Nerve repair promotes synaptic remodeling and regeneration of surviving nerve cells, including neuroregeneration and neurogenesis. Early thrombolytic therapy is currently recognized as the most effective method, but the treatment time window is narrow, and the indications must be strictly controlled. Currently, only about 3% to 5% of patients can receive thrombolytic therapy. Therefore, neuroprotection has become an important part of the treatment of ischemic stroke, which i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61P9/10A61P9/04
Inventor 蒋王林纪云霞徐洋亢泽春
Owner BINZHOU MEDICAL COLLEGE